Released: August 07, 2026
Abemaciclib [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2025.
Abu-Sbeih H, Ali FS, Wang Y. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol. 2020;38:576-583.
André F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:1816-1837.
Blum JL, Flynn PJ, Yothers G, et al. Long-term follow-up of the Anthracyclines in Early Breast Cancer (ABC) trials. J Clin Oncol. 2024;42:1100-1110.
Carboplatin [prescribing information]. New York, NY: Pfizer; 2025.
Cardoso F, O’Shaughnessy J, Liu Z, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER-positive/HER2-negative breast cancer: a randomized phase 3 trial. Nat Med. 2025;31:442-448.
Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717-729.
ClinicalTrials.gov. A single arm phase II study of adjuvant endocrine therapy and subcutaneous pertuzumab/trastuzumab fixed-dose combination for patients with anatomic stage I HR-positive/HER2-positive breast cancer (ADEPT). NCT04569747. Accessed July 2, 2026.
ClinicalTrials.gov. ShortStop-HER2: 12 months vs 6 months of HER2-targeted medications for people with HER2-positive breast cancer who had a pathologic complete response after chemotherapy plus trastuzumab. NCT06876714. Accessed July 2, 2026.
ClinicalTrials.gov. T-DM1 and tucatinib compared with T-DM1 alone in preventing relapses in people with high-risk HER2-positive breast cancer. NCT04457596. Accessed July 2, 2026.
Docetaxel [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2024.
Gao HF, Ye GL, Lin Y, et al. Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive breast cancer: the randomized noninferiority phase III neoCARHP trial. J Clin Oncol. 2026;44:1587-1596.
Garber JE, Gelber RD, Piccart M, et al. OlympiA: a phase 3, multicenter, randomized trial of adjuvant olaparib after chemotherapy in patients with germline BRCA1/2 mutation-associated high-risk HER2-negative early breast cancer. Clin Cancer Res. 2025;31(12 suppl):GS1-09.
Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
Harbeck N, Modi S, Pusztai L, et al; DESTINY-Breast11 Trial Investigators. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomized, open-label, multicenter, phase 3 trial. Ann Oncol. 2026;37:166-179.
Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3998.
Johnston SRD, Martin M, O’Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026;37:155-165.
Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early- stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013;14:1121-1128.
Jones SE, Savin MA, Holmes FA, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177-1183.
Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336-2347.
Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336-2347.
Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485-1505.
Loibl S, Park YH, Shao Z, et al; DESTINY-Breast05 Trial Investigators. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med. 2026;394:845-857.
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1688-1700.
Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-2159.
National Cancer Institute. Breast cancer TNM staging system. cancer.gov. Accessed July 1, 2026.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v5.2026. nccn.org. Accessed July 7, 2026.
Olaparib [prescribing information]. Wilmington, DE: AstraZeneca; 2025.
Olaparib prescribing Information. AstraZeneca Pharmaceuticals LP; 2025.
Paclitaxel [prescribing information]. Lake Forest, IL: Hospira, Inc.; 2025.
Pembrolizumab [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; 2026.
Rastogi P, O’Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, HER2- negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987-993.
Ribociclib [prescribing information]. East Hanover, NJ: Novartis; 2025.
Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
Schmid P, Cortes J, Dent R, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med.2024;391:1981-1991.
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomized, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27-35.
Sharma P, Stecklein SR, Yoder R, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024;10:227-235.
Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080-1091.
Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111-121.
Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380:2395-2405.
Tarantino P, Tayob N, Isakoff SJ, et al. Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I HER2-positive breast cancer: 5-year results and correlative analyses from ATEMPT. J Clin Oncol. 2024;42:3652-3665.
Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134-141.
Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, HER2-positive breast cancer. J Clin Oncol. 2019;37:1868-1875.
Tolaney SM, Tarantino P, Graham N, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023;24:273-285.
Trastuzumab [prescribing information]. South San Francisco, CA: Genentech; 2024.
Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2026.
Trivedi MS, Unger JM, Henry NL, et al. Risk prediction model for taxane-induced peripheral neuropathy in early-stage cancer. JAMA Netw Open. 2026;9:e264901.
Tung NM, et al. Secondary results from the EA1181/CompassHER2 pCR trial. J Clin Oncol. 2025;43(16 suppl):501.
Verzenio [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2025.
Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Selecting Systemic Therapy for Early Breast Cancer” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.
This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for patients with early-stage HR-positive/HER2-negative, HER2-positive, and triple-negative breast cancer (TNBC). The information provided is based on guideline recommendations and expert guidance of Shipra Gandhi, MD, MS; Tanya Gupta, MD; Reshma L. Mahtani, DO; Erica L. Mayer, MD, MPH; and Laura Spring, MD. The material published by Decera Clinical Education reflects the views of the reviewers or authors of the Decera Clinical Education material, not those of Decera Clinical Education, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Although the information contained in the “Interactive Decision Support Tool: Selecting Systemic Therapy for Early Breast Cancer” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education, including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.
Any trademarks are the property of respective companies.
©2026 Decera Clinical Education, LLC. All rights reserved.